US EditionAstraZeneca to acquire Modella AI to speed oncology drug research
AstraZeneca’s acquisition of Modella AI aims to enhance oncology research by integrating AI-driven pathology and biomarker discovery to improve clinical trial success rates.
- On Jan 13, AstraZeneca agreed to buy Boston-based Modella AI, announcing the deal in San Francisco during the J.P. Morgan Healthcare Conference; financial terms were not disclosed and AstraZeneca said this was the first AI firm acquisition by a big pharma company.
- Modella's technology will be integrated into AstraZeneca's oncology research and development, with AstraZeneca calling the prior partnership a "test drive" and seeking Modella's data, foundation models and AI talent in-house.
- The acquisition expands a multi-year collaboration unveiled in July and includes plans to build a new research lab using Nvidia's latest-generation AI chips.
- Gabi Raia said `Oncology drug development is becoming more complex, more data-rich and more time-sensitive,` and added that joining AstraZeneca would allow deployment of Modella's tools in global trials.
- AstraZeneca framed the move as the first of its kind by a big pharmaceutical company, amid several AI–pharma announcements at the J.P. Morgan Healthcare Conference, aligning with its $80 billion revenue target.
11 Articles
11 Articles
Artificial intelligence is to find new drugs faster. According to AstraZeneca, it is the first acquisition of an AI company by a large pharmaceutical company.
Modella AI Announces Acquisition by AstraZeneca
BOSTON–(BUSINESS WIRE)–Modella AI, a leader in artificial intelligence for life sciences, today announced that it has been acquired by AstraZeneca, expanding the companies’ existing collaboration to advance the application of multi-modal AI foundation models and AI agents across AstraZeneca’s global oncology portfolio. The acquisition follows a multi-year agreement with AstraZeneca announced in July 2025 and will integrate Modella AI’s generativ…
AstraZeneca headquarters in Switzerland. Image by Bigstock AstraZeneca has agreed to the acquisition of the American technology company Modella AI, based in Boston, in a strategic movement to boost its research into cancer through artificial intelligence, at a time when the pharmaceutical industry is accelerating its adoption of advanced technologies. Although the companies did not disclose the financial terms of the agreement, they pointed out …
AstraZeneca is taking the next step in the AI revolution in medicine: The pharmaceutical giant is acquiring the US start-up Modella AI to significantly accelerate the development of new cancer drugs.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
